Gilead Sciences Inc. has signed, a non-exclusive voluntary licensing agreement with four Indian companies which include Cipla, Jubilant, Hetero, Mylan and Ferozsons. Gilead Sciences is a United States-based company. The signed licensing deal is for the manufacturing of Remdesivir, an identified drug which could be effective for the treatment of Covid19. The agreement is not only for India but also 127 low, middle income and upper-middle-income countries. The agreement allows all five companies to manufacture the drug and have them distributed to the other 127 countries. The US-based company made this known in a release made on Tuesday. Gilead said, “The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid19, or until a pharmaceutical product other than Remdesivir or a vaccine is approved”.
In April Remdesivir received approval from the US Food and Drug Administration, the approval was given based on good results shown by the drug. As part of the agreement, all five companies involved have a right to receive a technology transfer to enable them to scale up production. The license also allows different companies to set their prices for the product they produce. Jubilant Generic Ltd said “we are very happy to strengthen our partnership with Gilead to license Remdesivir, which based on initial data, shows promise to be a potential therapy for covid19. Remdesivir is yet to be approved as a cure against covid19 by the US drug regulator